pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 42 | Non-oncology: 27 Oncology: 15 |
| Under Consideration for Negotiation | 17 | Non-oncology: 11 Oncology: 6 |
| Completed Negotiations | 840 | With Letter of Intent: 730 Without agreement: 110 |
| Negotiations That Were Not Pursued | 111 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Lazcluze and Rybrevant | Janssen Inc. | For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations | |
| Polivy | Hoffmann-La Roche Ltd. | In combination with R-CHP for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (E | |
| Opdivo SC | Bristol Myers Squibb Canada Inc. | Multiple Indications | |
| Methofill | Accord Healthcare Inc. | Multiple Indications | |
| Nordimet | Nordic Pharma | Multiple Indications | |
| Ferinject | CSL Vifor | Iron Deficiency Anemia | |
| Ferinject | CSL Vifor | Iron deficiency in adult patients with heart failure | |
| Iqirvo | Ipsen Biopharmaceuticals Canada, Inc. | Primary biliary cholangitis | |
| Skyclarys | Biogen Canada Inc. | Friedreich’s ataxia | |
| Sogroya | Novo Nordisk Canada Inc. | Growth hormone deficiency |